Glutathione‐Related Metabolite Levels and Enzyme Activities in Depression: A Systematic Review and Meta‐Analysis

Recently, an increasing number of studies have reported abnormal levels of glutathione (GSH)-related metabolites and enzyme activities in neuroimaging and peripheral samples in patients with depression, indicating abnormalities in the GSH cycle in patients with depression. However, the abnormalities in the GSH cycle have not been comprehensively investigated. Here, we conducted a systematic review and meta-analysis to compare the levels of GSH-related metabolites (GSH and GSH disulfide [GSSG]) and the activities of GSH-related enzymes (Glutathione-peroxidase [GPx], GSH reductase [GR], glutamate-cysteine ligase [GCL], GSH synthetase [GS], and GSH S-transferase [GST]) between patients with depression and healthy controls (HC). The search was performed with MEDLINE, Embase, and PsychINFO. The inclusion criteria were studies comparing levels of GSH-related metabolites and enzyme activities between patients with depression and HC. Standardized mean differences were calculated to assess group differences. Thirty studies met the eligibility criteria, which included 1019 patients and 947 HC. Our meta-analysis indicated significantly decreased activity of GPx in patients with depression compared with HC, while the levels of GSH and GR were not significantly different between the groups. Because no studies, or an insufficient number of studies, have been conducted on GSSG, GST, GCL, and GS, meta-analyses were not performed for these metabolites and enzyme activities. Our findings suggest that abnormal cycling of the GSH system, particularly decreased GPx activity, is involved in the pathophysiology of depression and may serve as a potential biomarker for this illness. Furthermore, given that no or insufficient studies have been conducted on GSSG, GST, GCL, and GS, this study highlights the need for further research to fully elucidate the GSH cycle in patients with depression.

Authors

Institutions

Publication Details

Journal
Neuropsychopharmacology Reports
Published
2026-04-30
DOI
https://doi.org/10.1002/npr2.70125
Primary Topic
Tryptophan and brain disorders
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Glutathione‐Related Metabolite Levels and Enzyme Activities in Depression: A Systematic Review and Meta‐Analysis

Hikari Segawa, Nobuaki Hondo, K Yoshida, Sho Moriguchi et al.
Neuropsychopharmacology Reports
Tryptophan and brain disorders
article

Glutathione‐Related Metabolite Levels and Enzyme Activities in Depression: A Systematic Review and Meta‐Analysis

Hikari Segawa, Nobuaki Hondo, K Yoshida, Sho Moriguchi, Masataka Wada, Ryoma Kani, Sotaro Moriyama, Shiori Honda, Yumina Nakamura, Takahide Etani, Y Mori, Tony Kaku, Koki Takahashi, Sakiko Tsugawa, Hiroyuki Uchida, Shinichiro Nakajima, Tahichi Moritake
article en

Abstract

Recently, an increasing number of studies have reported abnormal levels of glutathione (GSH)-related metabolites and enzyme activities in neuroimaging and peripheral samples in patients with depression, indicating abnormalities in the GSH cycle in patients with depression. However, the abnormalities in the GSH cycle have not been comprehensively investigated. Here, we conducted a systematic review and meta-analysis to compare the levels of GSH-related metabolites (GSH and GSH disulfide [GSSG]) and the activities of GSH-related enzymes (Glutathione-peroxidase [GPx], GSH reductase [GR], glutamate-cysteine ligase [GCL], GSH synthetase [GS], and GSH S-transferase [GST]) between patients with depression and healthy controls (HC). The search was performed with MEDLINE, Embase, and PsychINFO. The inclusion criteria were studies comparing levels of GSH-related metabolites and enzyme activities between patients with depression and HC. Standardized mean differences were calculated to assess group differences. Thirty studies met the eligibility criteria, which included 1019 patients and 947 HC. Our meta-analysis indicated significantly decreased activity of GPx in patients with depression compared with HC, while the levels of GSH and GR were not significantly different between the groups. Because no studies, or an insufficient number of studies, have been conducted on GSSG, GST, GCL, and GS, meta-analyses were not performed for these metabolites and enzyme activities. Our findings suggest that abnormal cycling of the GSH system, particularly decreased GPx activity, is involved in the pathophysiology of depression and may serve as a potential biomarker for this illness. Furthermore, given that no or insufficient studies have been conducted on GSSG, GST, GCL, and GS, this study highlights the need for further research to fully elucidate the GSH cycle in patients with depression.

Neuropsychopharmacology ReportsVol. 46(2)
Centre for Addiction and Mental Health (CA), Keio University (JP), Stony Brook School (US), Ashikaga Red Cross Hospital (JP), Keio University Hospital (JP), Kameda Medical Center (JP), National Institutes for Quantum Science and Technology (JP), National Hospital Organization (JP), Keio University Shonan Fujisawa (JP), Stony Brook University (US), Yokohama City University (JP), Stanford University (US)
Watanabe Foundation, Naito Foundation, Takeda Science Foundation, Japan Research Foundation for Clinical Pharmacology, Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science
Openalex Percentile: Top 14%
Tryptophan and brain disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.